Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof

Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof

US Patent 11497746 · Granted Nov 15, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Modulating gabarap to modulate immunogenic cell death2024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD32024
Methods for modulating regulatory T cells, regulatory b cells, and immune respon2024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and epoth2024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and an au2024
HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chron2023
HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chron2023
Small molecules for inducing selective protein degradation and uses thereof2023
Small molecules that block proteasome-associated ubiquitin receptor RPN13 functi2023